Desensitization protocol and outcomes
| Patient number | Induction agent | Dose of rituximab (mg) | Baseline anti-ABO antibody titer | Anti-ABO antibody titer, preop | Session | Creatinine (µmol/L) | Duration of follow-up (mo) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-Tx PEX | Post-Tx PEX | Discharge | 1 month | Current | |||||||
| 1 | Basiliximab | 100 | 1:128 | 1:8 | 03 | 00 | 170 | 207 | 213 | 76 | |
| 2 | Basiliximab | 100 | 1:32 | 1:2 | 03 | 00 | 172 | 198 | 316 | 72 | |
| 3 | Basiliximab | 100 | 1:64 | 1:4 | 03 | 00 | 244 | 188 | - | 6 | |
| 4 | Basiliximab | 100 | 1:64 | 1:4 | 03 | 00 | 191 | 192 | 167 | 54 | |
| 5 | Basiliximab | 100 | 1:64 | 1:4 | 03 | 00 | 229 | 184 | 183 | 47 | |
| 6 | Basiliximab | 100 | 1:32 | 1:8 | 05 | 00 | 84 | 119 | - | 2 | |
| 7 | Basiliximab | 100 | 1:128 | 1:8 | 03 | 00 | 96 | 127 | 167 | 23 | |
Preop, preoperative; Pre-Tx, pretransplant; Post-Tx, posttransplant; PEX, plasma exchange.